Immunological basis for enhanced immunity of nanoparticle vaccines

References

• WHO. WHO Immunization [Internet]. [cited 2019 Jan 4]. Available from: http://www.who.int/topics/immunization/en/.
   Google Scholar
• Laouini D, Kennou MF, Khoufi S, et al. Antibodies to human myelin proteins and gangliosides in patients with acute neuroparalytic accidents induced by brain-derived rabies vaccine. J Neuroimmunol. 1998;91:63–72.
   PubMed Web of Science ®Google Scholar
• Shaghaghi M, Soleyman-Jahi S, Abolhassani H, et al. New insights into physiopathology of immunodeficiency-associated vaccine-derived poliovirus infection; systematic review of over 5 decades of data. Vaccine. 2018;36:1711–1719. Available from. [Internet].
   PubMed Web of Science ®Google Scholar
• Karch CP, Burkhard P. Vaccine technologies: from whole organisms to rationally designed protein assemblies. Biochem Pharmacol. 2016;120:1–14.
   PubMed Web of Science ®Google Scholar
• Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380:2095–2128.
   PubMed Web of Science ®Google Scholar
• Kaufmann SHE, Juliana McElrath M, Lewis DJM, et al. Challenges and responses in human vaccine development. Curr Opin Immunol. [Internet]. 2014;28:18–26.
   PubMed Web of Science ®Google Scholar
• Kanekiyo M, Wei C-J, Yassine HM, et al. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature. [Internet]. 2013;499:102–106. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23698367
   PubMed Web of Science ®Google Scholar
• Keller S, Wilson TJ, Patilea GI, et al. Neutral polymer micelle carriers with pH-responsive, endosome-releasing activity modulate antigen trafficking to enhance CD8+T cell responses. J Control Release. [Internet]. 2014;191:24–33.
   PubMed Web of Science ®Google Scholar
• Kang S, Ahn S, Lee J, et al. Effects of gold nanoparticle-based vaccine size on lymph node delivery and cytotoxic T-lymphocyte responses. J Control Release. [Internet]. 2017;256:56–67.
   PubMed Web of Science ®Google Scholar
• Rahimian S, Kleinovink JW, Fransen MF, et al. Near-infrared labeled, ovalbumin loaded polymeric nanoparticles based on a hydrophilic polyester as model vaccine: invivo tracking and evaluation of antigen-specific CD8+ T cell immune response. Biomaterials. 2015;37:469–477.
   PubMed Web of Science ®Google Scholar
• Valenzuela P, Medina A, Rutter WJ, et al. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature. 1982;298:347–350.
   PubMed Web of Science ®Google Scholar
• Partnership SCT. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. [Internet]. 2015;386:31–45.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Human papillomavirus vaccines: WHO position paper, May 2017. Wkly Epidemiol Rec. [Internet]. 2017;92:241–268. Available from: http://www.who.int/wer.
   PubMedGoogle Scholar
• Breitburd F, Kirnbauer R, Hubbert N, et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol. 1995;69:3959–3963.
   PubMed Web of Science ®Google Scholar
• Romanowski B, Schwarz TF, Ferguson LM, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose schedule. Hum Vaccin. [Internet]. 2011;7:1374–1386. Available from: http://www.tandfonline.com/doi/abs/10.4161/hv.7.12.18322
   PubMed Web of Science ®Google Scholar
• Schiller J, Lowy D. Explanations for the high potency of HPV prophylactic vaccines. Vaccine. [Internet]. 2018;36:4768–4773.
   PubMed Web of Science ®Google Scholar
• Kushnir N, Streatfield SJ, Yusibov V. Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine. [Internet]. 2012;31:58–83.
   PubMed Web of Science ®Google Scholar
• Wu T, Li SW, Zhang J, et al. Hepatitis E vaccine development: a 14-year odyssey. Hum Vaccines Immunother. 2012;8:823–827.
   PubMed Web of Science ®Google Scholar
• Spohn G, Jennings GT, Martina BE, et al. A VLP-based vaccine targeting domain III of the West Nile virus e protein protects from lethal infection in mice. Virol J. 2010;6:146.
   Google Scholar
• Herzog C, Hartmann K, Künzi V, et al. Eleven years of Inflexal®V-a virosomal adjuvanted influenza vaccine. Vaccine. 2009;27:4381–4387.
   PubMed Web of Science ®Google Scholar
• Bovier PA. Epaxal®: a virosomal vaccine to prevent hepatitis A infection. Expert Rev Vaccines. 2008;7:1141–1150.
   PubMed Web of Science ®Google Scholar
• Albanese A, Tang PS, Chan WCW. [Review] The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng. 2012;14:1–16. .
   PubMed Web of Science ®Google Scholar
• Oyewumi MO, Kumar A, Cui Z. Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev Vaccines. 2010;9:1095–1107.
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol. [Internet]. 2010;10:787–796. .
   PubMed Web of Science ®Google Scholar
• Manolova V, Flace A, Bauer M, et al. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol. 2008;38:1404–1413.
   PubMed Web of Science ®Google Scholar
• Li X, Sloat BR, Yanasarn N, et al. Relationship between the size of nanoparticles and their adjuvant activity: data from a study with an improved experimental design. Eur J Pharm Biopharm. [Internet]. 2011;78:107–116.
   PubMed Web of Science ®Google Scholar
• Dykman LA, Staroverov SA, Fomin AS, et al. Gold nanoparticles as an adjuvant: influence of size, shape, and technique of combination with CpG on antibody production. Int Immunopharmacol. 2018;54:163–168.
   PubMed Web of Science ®Google Scholar
• Bruckman MA, Randolph LN, VanMeter A, et al. Biodistribution, pharmacokinetics, and blood compatibility of native and PEGylated tobacco mosaic virus nano-rods and -spheres in mice. Virology. [Internet]. 2014;449:163–173.
   PubMed Web of Science ®Google Scholar
• Fromen CA, Robbins GR, Shen TW, et al. Controlled analysis of nanoparticle charge on mucosal and systemic antibody responses following pulmonary immunization. Proc Natl Acad Sci. [Internet]. 2015;112:488–493.DOI:10.1073/pnas.1422923112.
   PubMed Web of Science ®Google Scholar
• Fromen CA, Rahhal TB, Robbins GR, et al. Nanoparticle surface charge impacts distribution, uptake and lymph node trafficking by pulmonary antigen-presenting cells. Nanomedicine Nanotechnology, Biol Med. [Internet]. 2016;12:677–687.
   PubMed Web of Science ®Google Scholar
• Foged C, Brodin B, Frokjaer S, et al. Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int J Pharm. 2005;298:315–322.
   PubMed Web of Science ®Google Scholar
• Moyano DF, Goldsmith M, Solfiell DJ, et al. Nanoparticle hydrophobicity dictates immune response. J Am Chem Soc. 2012;134:3965–3967.
   PubMed Web of Science ®Google Scholar
• Faria M, Björnmalm M, Thurecht KJ, et al. Minimum information reporting in bio–nano experimental literature. Nat Nanotechnol. 2018;13:777–785.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Hu Y, Hoerle R, et al. A nanoparticle-based nicotine vaccine and the influence of particle size on its immunogenicity and efficacy. Nanomedicine Nanotechnology, Biol Med. 2017;13:443–454.
   PubMed Web of Science ®Google Scholar
• Mueller SN, Tian S, Desimone JM. Rapid and persistent delivery of antigen by lymph node targeting PRINT nanoparticle vaccine carrier to promote humoral immunity. Mol Pharm. 2015;12:1356–1365.
   PubMedGoogle Scholar
• Sliepen K, Ozorowski G, Burger JA, et al. Presenting native ‑ like HIV ‑ 1 envelope trimers on ferritin nanoparticles improves their immunogenicity. Retrovirology. 2015;12:82.
   PubMed Web of Science ®Google Scholar
• Leneghan DB, Miura K, Taylor IJ, et al. Nanoassembly routes stimulate conflicting antibody quantity and quality for transmission-blocking malaria vaccines. Sci Rep. 2017;7:3811.
   PubMed Web of Science ®Google Scholar
• Bale S, Goebrecht G, Stano A, et al. Covalent linkage of HIV-1 trimers to synthetic liposomes elicits improved B cell and antibody responses. J Virol. [Internet]. 2017;91:e00443–e00517.DOI:10.1128/JVI.00443-17.
   PubMed Web of Science ®Google Scholar
• Holt BA, Bellavia MC, Potter D, et al. Fc microparticles can modulate the physical extent and magnitude of complement activity. Biomater Sci. 2017;5:463–474.
   PubMed Web of Science ®Google Scholar
• Thompson EA, Ols S, Miura K, et al. TLR-adjuvanted nanoparticle vaccines differentially influence the quality and longevity of responses to malaria antigen Pfs25. JCI Insight. 2018;3:e120692. .
   PubMed Web of Science ®Google Scholar
• Ingale J, Stano A, Guenaga J, et al. High-density array of well-ordered HIV-1 spikes on synthetic liposomal nanoparticles efficiently activate B cells. Cell Rep. [Internet]. 2016;15:1986–1999.
   PubMed Web of Science ®Google Scholar
• Tsoras AN, Champion JA. Cross-linked peptide nanoclusters for delivery of oncofetal antigen as a cancer vaccine. Bioconjug Chem. 2018;29:776–785.
   PubMed Web of Science ®Google Scholar
• Glass JJ, Yuen D, Rae J, et al. Human immune cell targeting of protein nanoparticles – caveospheres. Nanoscale. [Internet]. 2016;8:8255–8265. Available from: http://xlink.rsc.org/?DOI=C6NR00506C
   PubMed Web of Science ®Google Scholar
• Pavot V, Rochereau N, Primard C, et al. Encapsulation of Nod1 and Nod2 receptor ligands into poly(lactic acid) nanoparticles potentiates their immune properties. J Control Release. [Internet]. 2013;167:60–67.
   PubMed Web of Science ®Google Scholar
• Ajdary M, Moosavi M, Rahmati M, et al. Health concerns of various nanoparticles: a review of their in vitro and in vivo toxicity. Nanomaterials. [Internet]. 2018;8:634. Available from: http://www.mdpi.com/2079-4991/8/9/634
   Web of Science ®Google Scholar
• Onoue S, Yamada S, Chan HK. Nanodrugs: pharmacokinetics and safety. Int J Nanomedicine. 2014;9:1025–1037.
   PubMed Web of Science ®Google Scholar
• Braakhuis HM, Gosens I, Krystek P, et al. Particle size dependent deposition and pulmonary inflammation after short-term inhalation of silver nanoparticles. Part Fibre Toxicol. 2014;11:49.
   PubMed Web of Science ®Google Scholar
• Bros M, Nuhn L, Simon J, et al. The protein corona as a confounding variable of nanoparticle-mediated targeted vaccine delivery. Front Immunol. 2018;9:1760. .
   PubMed Web of Science ®Google Scholar
• Zhang H, Burnum KE, Luna ML, et al. Quantitative proteomics analysis of adsorbed plasma proteins classifies nanoparticles with different surface properties and size. Proteomics. 2011;11:4569–4577.
   PubMed Web of Science ®Google Scholar
• Palchetti S, Digiacomo L, Pozzi D, et al. Nanoparticles-cell association predicted by protein corona fingerprints. Nanoscale. [Internet]. 2016;7:779–786. Available from: http://xlink.rsc.org/?DOI=C6NR03898K
   Google Scholar
• Shen L, Tenzer S, Storck W, et al. Protein corona–mediated targeting of nanocarriers to B cells allows redirection of allergic immune responses. J Allergy Clin Immunol. 2018;142:1558–1570.
   PubMed Web of Science ®Google Scholar
• Grenier P, de Oliveira Viana IM, Lima EM, et al. Anti-polyethylene glycol antibodies alter the protein corona deposited on nanoparticles and the physiological pathways regulating their fate in vivo. J Control Release. [Internet]. 2018;287:121–131. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0168365918304887
   PubMed Web of Science ®Google Scholar
• Tavano R, Gabrielli L, Lubian E, et al. C1q-mediated complement activation and C3 opsonization trigger recognition of stealth Poly(2-methyl-2-oxazoline)-coated silica nanoparticles by human phagocytes. ACS Nano. 2018;12:5834–5847.
   PubMed Web of Science ®Google Scholar
• Liu Y, Yin Y, Wang L, et al. Engineering biomaterial-associated complement activation to improve vaccine efficacy. Biomacromolecules. 2013;14:3321–3328.
   PubMed Web of Science ®Google Scholar
• Chen F, Wang G, Griffin JI, et al. Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo. Nat Nanotechnol. 2017;12:387–393.
   PubMed Web of Science ®Google Scholar
• Diebolder CA, Beurskens FJ, De Jong RN, et al. Complement is activated by IgG hexamers assembled at the cell surface. Science. 2014;343:1260–1263.
   PubMed Web of Science ®Google Scholar
• Link A, Zabel F, Schnetzler Y, et al. Innate immunity mediates follicular transport of particulate but not soluble protein antigen. J Immunol. [Internet] 2012;188:3724–3733. Available from http://www.jimmunol.org/cgi/doi/10.4049/jimmunol.1103312 .
   PubMed Web of Science ®Google Scholar
• Jennings GT, Bachmann MF. The coming of age of virus-like particle vaccines. Biol Chem. 2008;389:521–536.
   PubMed Web of Science ®Google Scholar
• Phan TG, Grigorova I, Okada T, et al. Subcapsular encounter and complement-dependent transport of immune complexes by lymph node B cells. Nat Immunol. 2007;8:992–1000.
   PubMed Web of Science ®Google Scholar
• Silva AL, Rosalia RA, Varypataki E, et al. Poly-(lactic-co-glycolic-acid)-based particulate vaccines: particle uptake by dendritic cells is a key parameter for immune activation. Vaccine. [Internet]. 2015;33:847–854.
   PubMed Web of Science ®Google Scholar
• Hu X, Deng Y, Chen X, et al. Immune response of a novel ATR-AP205-001 conjugate anti-hypertensive vaccine. Sci Rep. [Internet]. 2017;7:12580.
   PubMed Web of Science ®Google Scholar
• Speiser DE, Schwarz K, Baumgaertner P, et al. Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. J Immunother. 2010;33:848–858.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Harris B, Hu Y, et al. Rational incorporation of molecular adjuvants into a hybrid nanoparticle-based nicotine vaccine for immunotherapy against nicotine addiction. Biomaterials. [Internet]. 2018;155:165–175.
   PubMed Web of Science ®Google Scholar
• Kasturi SP, Skountzou I, Albrecht RA, et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature. 2011;470:543–550.
   PubMed Web of Science ®Google Scholar
• Hou B, Saudan P, Ott G, et al. Selective utilization of toll-like receptor and Myd88 signaling in B cells for enhancement of the antiviral germinal center response. Immunity. [Internet]. 2011;34:375–384.
   PubMed Web of Science ®Google Scholar
• Mohsen MO, Gomes AC, Cabral-Miranda G, et al. Delivering adjuvants and antigens in separate nanoparticles eliminates the need of physical linkage for effective vaccination. J Control Release. [Internet]. 2017;251:92–100.
   PubMed Web of Science ®Google Scholar
• Gomes AC, Flace A, Saudan P, et al. Adjusted particle size eliminates the need of linkage of antigen and adjuvants for appropriated T cell responses in virus-like particle-based vaccines. Front Immunol. 2017;8:226.
   PubMed Web of Science ®Google Scholar
• Krieg AM. Therapeutic potential of toll-like receptor 9 activation. Nat Rev Drug Discov. 2006;5:471–484.
   PubMed Web of Science ®Google Scholar
• Savage P, Horton V, Moore J, et al. A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily. Br J Cancer. 1996;74:1482–1486.
   PubMed Web of Science ®Google Scholar
• Liang F, Lindgren G, Sandgren KJ, et al. Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake. Sci Transl Med. [Internet]. 2017;9:eaal2094. Available from: http://stm.sciencemag.org/lookup/doi/10.1126/scitranslmed.aal2094
   PubMed Web of Science ®Google Scholar
• Reddy ST, van der Vlies AJ, Simeoni E, et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Eur Cells Mater. 2007;25:1159–1164.
   Google Scholar
• Reddy ST, Rehor A, Schmoekel HG, et al. In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J Control Release. 2006;112:26–34.
   PubMed Web of Science ®Google Scholar
• Knopf PM, Rivera DS, Hai SH, et al. Novel function of complement C3d as an autologous helper T-cell target. Immunol Cell Biol. 2008;86:221–225.
   PubMed Web of Science ®Google Scholar
• Carter RH, Fearon DT. CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science. 1992;256:105–107.
   PubMed Web of Science ®Google Scholar
• Rioux G, Carignan D, Russell A, et al. Influence of PapMV nanoparticles on the kinetics of the antibody response to flu vaccine. J Nanobiotechnology. 2016;14:1–9.
   PubMed Web of Science ®Google Scholar
• Bennett NR, Zwick DB, Courtney AH, et al. Multivalent antigens for promoting B and T cell activation. ACS Chem Biol. 2015;10:1817–1824.
   PubMed Web of Science ®Google Scholar
• Yang J, Reth M. Oligomeric organization of the B-cell antigen receptor on resting cells. Nature. [Internet]. 2010;467:465–469.
   PubMed Web of Science ®Google Scholar
• Puffer EB, Pontrello JK, Hollenbeck JJ, et al. Activating B cell signaling with defined multivalent ligands. ACS Chem Biol. 2007;2:252–262.
   PubMed Web of Science ®Google Scholar
• Batista FD, Neuberger MS. B cells extract and present immobilized antigen: implications for affinity discrimination. Embo J. 2000;19:513–520.
   PubMed Web of Science ®Google Scholar
• Temchura VV, Kozlova D, Sokolova V, et al. Targeting and activation of antigen-specific B-cells by calcium phosphate nanoparticles loaded with protein antigen. Biomaterials. [Internet]. 2014;35:6098–6105.
   PubMed Web of Science ®Google Scholar
• Kim Y-M, Pan -JY-J, Korbel GA, et al. Monovalent ligation of the B cell receptor induces receptor activation but fails to promote antigen presentation. Proc Natl Acad Sci. [Internet]. 2006;103:3327–3332.
   PubMed Web of Science ®Google Scholar
• Zeng Y, Yi J, Wan Z, et al. Substrate stiffness regulates B-cell activation, proliferation, class switch, and T-cell-independent antibody responses in vivo. Eur J Immunol. 2015;45:1621–1634.
   PubMed Web of Science ®Google Scholar
• Abbott RK, Lee JH, Menis S, et al. Precursor frequency and affinity determine B cell competitive fitness in germinal centers, tested with germline-targeting HIV vaccine immunogens. Immunity. [Internet]. 2018;48:133–146.e6.
   PubMed Web of Science ®Google Scholar
• Harris AK, Meyerson JR, Matsuoka Y, et al. Structure and accessibility of HA trimers on intact 2009 H1N1 pandemic influenza virus to stem region-specific neutralizing antibodies. Proc Natl Acad Sci. 2013;110:4592–4597.
   PubMed Web of Science ®Google Scholar
• Zhu P, Liu J, Bess J, et al. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature. 2006;441:847–852.
   PubMed Web of Science ®Google Scholar
• Brewer MG, DiPiazza A, Acklin J, et al. Nanoparticles decorated with viral antigens are more immunogenic at low surface density. Vaccine. [Internet]. 2017;35:774–781. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0264410X16312749
   PubMed Web of Science ®Google Scholar
• Hanson MC, Abraham W, Crespo MP, et al. Liposomal vaccines incorporating molecular adjuvants and intrastructural T-cell help promote the immunogenicity of HIV membrane-proximal external region peptides. Vaccine. [Internet]. 2015;33:861–868.
   PubMed Web of Science ®Google Scholar
• Benen TD, Tonks P, Kliche A, et al. Development and immunological assessment of VLP-based immunogens exposing the membrane-proximal region of the HIV-1 gp41 protein. J Biomed Sci. 2014;21:79.
   PubMed Web of Science ®Google Scholar
• Ding P, Zhang T, Li Y, et al. Nanoparticle orientationally displayed antigen epitopes improve neutralizing antibody level in a model of porcine circovirus type 2. Int J Nanomedicineb. 2017;12:5239–5254.
   PubMed Web of Science ®Google Scholar
• Georgiev IS, Joyce MG, Chen RE, et al. Two-component ferritin nanoparticles for multimerization of diverse trimeric antigens. ACS Infect Dis. [Internet]. 2018;4:788–796.
   PubMed Web of Science ®Google Scholar
• Lindgren G, Ols S, Liang F, et al. Induction of Robust B cell responses after influenza mRNA vaccination is accompanied by circulating hemagglutinin-specific ICOS+ PD-1+ CXCR3+ T follicular helper cells. Front Immunol. 2017;8:1539.
   PubMed Web of Science ®Google Scholar
• Tuaillon E, Al Tabaa Y, Petitjean G, et al. Detection of memory B lymphocytes specific to hepatitis B virus (HBV) surface antigen (HBsAg) from HBsAg-vaccinated or HBV-immunized subjects by ELISPOT assay. J Immunol Methods. 2006;315:144–152.
   PubMed Web of Science ®Google Scholar
• Moreira L, Neto M, Zufelato N, et al. Specific T cell induction using iron oxide based nanoparticles as subunit vaccine adjuvant. Hum Vaccin Immunother. 2018;14:2786–2801.
   Google Scholar
• Wang M, Jokinen J, Tretyakova I, et al. Alphavirus vector-based replicon particles expressing multivalent cross-protective Lassa virus glycoproteins. Vaccine. [Internet]. 2017;36:683–690.
   PubMed Web of Science ®Google Scholar
• Molino NM, Anderson AKL, Nelson EL, et al. Biomimetic protein nanoparticles facilitate enhanced dendritic cell activation and cross-presentation. ACS Nano. 2013;7:9743–9752.
   PubMed Web of Science ®Google Scholar
• Liu L, Ma P, Wang H, et al. Immune responses to vaccines delivered by encapsulation into and/or adsorption onto cationic lipid-PLGA hybrid nanoparticles. J Control Release. [Internet]. 2016;225:230–239.
   PubMed Web of Science ®Google Scholar
• Pardi N, Hogan MJ, Naradikian MS, et al. Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J Exp Med. [Internet]. 2018;215:1571–1588.
   PubMed Web of Science ®Google Scholar
• Moon JJ, Suh H, Li AV, et al. Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction. Proc Natl Acad Sci. [Internet]. 2012:109:1080–1085. .
   PubMed Web of Science ®Google Scholar
• Ishii N, Fitrilawati F, Manna A, et al. Gold nanoparticles used as a carrier enhance production of anti-hapten IgG in rabbit: a study with Azobenzene-Dye as a Hapten presented on the entire surface of gold nanoparticles. Biosci Biotechnol Biochem. [Internet]. 2008;72:124–131. Available from: http://www.tandfonline.com/doi/full/10.1271/bbb.70499
   PubMed Web of Science ®Google Scholar
• Moser C, Müller M, Kaeser MD, et al. Influenza virosomes as vaccine adjuvant and carrier system. Expert Rev Vaccines. 2013;12:779–791.
   PubMed Web of Science ®Google Scholar
• Peduzzi E, Westerfeld N, Zurbriggen R, et al. Contribution of influenza immunity and virosomal-formulated synthetic peptide to cellular immune responses in a phase I subunit malaria vaccine trial. Clin Immunol. 2008;127:188–197.
   PubMed Web of Science ®Google Scholar
• Mattiacio J, Walter S, Brewer M, et al. Dense display of HIV-1 envelope spikes on the lambda phage scaffold does not result in the generation of improved antibody responses to HIV-1 Env. Vaccine. [Internet]. 2011;29:2637–2647.
   PubMed Web of Science ®Google Scholar
• Jegerlehner A, Wiesel M, Dietmeier K, et al. Carrier induced epitopic suppression of antibody responses induced by virus-like particles is a dynamic phenomenon caused by carrier-specific antibodies. Vaccine. [Internet]. 2010;28:5503–5512.
   PubMed Web of Science ®Google Scholar
• De Filette M, Martens W, Smet A, et al. Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies. Vaccine. 2008;26:6503–6507.
   PubMed Web of Science ®Google Scholar